Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Rhabdomyosarcomas (RMS) are the most common pediatric soft tissue sarcomas. They resemble developing skeletal muscle and are histologically divided into two main subtypes; alveolar and embryonal RMS. Characteristic genomic aberrations, including the PAX3‐ and PAX7‐FOXO1 fusion genes in alveolar cases, have led to increased understanding of their molecular biology. Here, we determined the effect of genomic copy number on gene expression levels through array comparative genomic hybridization (CGH) analysis of 13 RMS cell lines, confirmed by multiplex ligation‐dependent probe amplification copy number analyses, combined with their corresponding expression profiles. Genes altered at the transcriptional level by genomic imbalances were identified and the effect on expression was proportional to the level of genomic imbalance. Extrapolating to a public expression profiling dataset for 132 primary RMS identified features common to the cell lines and primary samples and associations with subtypes and fusion gene status. Genes identified such as CDK4 and MYCN are known to be amplified, overexpressed, and involved in RMS tumorigenesis. Of the many genes identified, those with likely functional relevance included CENPF, DTL, MYC, EYA2, and FGFR1. Copy number and expression of FGFR1 was validated in additional primary material and found amplified in 6 out of 196 cases and overexpressed relative to skeletal muscle and myoblasts, with significantly higher expression levels in the embryonal compared with alveolar subtypes. This illustrates the ability to identify genes of potential significance in tumor development through combining genomic and transcriptomic profiles from representative cell lines with publicly available expression profiling data from primary tumors. © 2009 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Banks, D., Wu, M., Higa, L. A., Gavrilova, N., Quan, J., Ye, T., Kobayashi, R., Sun, H., & Zhang, H. (2006) · Cell Cycle · doi:10.4161/cc.5.15.3150 · Cited by 127
Cited by
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Fibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 534
Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
Dutt, A., Ramos, A. H., Hammerman, P. S., Mermel, C., Cho, J., Sharifnia, T., Chande, A., Tanaka, K. E., Stransky, N., Greulich, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020351 · Cited by 369
Fibroblast growth factor receptors as treatment targets in clinical oncology
Katoh, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0115-y · Cited by 352
Chae, Y. K., Ranganath, K., Hammerman, P. S., Vaklavas, C., Mohindra, N., Kalyan, A., Matsangou, M., Costa, R., Carneiro, B., Villaflor, V. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14109 · Cited by 298
Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls
Hinson, A. R. P., Jones, R., Crose, L. E. S., Belyea, B. C., Barr, F. G., & Linardic, C. M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00183 · Cited by 192
MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL
Baraniskin, A., Birkenkamp-Demtroder, K., Maghnouj, A., Zöllner, H., Munding, J., Klein-Scory, S., Reinacher-Schick, A., Schwarte-Waldhoff, I., Schmiegel, W., & Hahn, S. A. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs020 · Cited by 142
The Unique Expression and Function of miR-424 in Human Placental Trophoblasts1
Mouillet, J.-F., Donker, R. B., Mishima, T., Cronqvist, T., Chu, T., & Sadovsky, Y. (2013) · Biology of Reproduction · doi:10.1095/biolreprod.113.110049 · Cited by 47
“Deregulated FGF signaling is also common in many types of cancers, and FGFR1 amplification has also been reported in breast cancers [52], oral squamous carcinoma [53], ovarian cancer [54], bladder cancer [55], and rhabdomyosarcoma [56].”
BackgroundA call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma
Olanich, M. E., & Barr, F. G. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.772136 · Cited by 39
Metadata
- Authors
- Missiaglia, E., Selfe, J., Hamdi, M., Williamson, D., Schaaf, G., Fang, C., Koster, J., Summersgill, B., Messahel, B., Versteeg, R., Pritchard‐Jones, K., Kool, M., & Shipley, J.
- Venue
- Genes, Chromosomes and Cancer
- Publisher
- Wiley
- Published
- 2009-02-23
- Volume
- 48
- Issue
- 6
- Pages
- 455-467
- ISSN
- 1045-2257 (ISSN-L)
- 1098-2264
- OpenAlex
- W2158730662
- Cited by
- 108
- References
- 1
- FWCI
- 7.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.